Low-Intensity Ultrasound for Mild Alzheimer's Symptoms

Low-Intensity Focused Ultrasound (LIFU) Neuromodulation

Recruiting N/A Interventional Study
Alzheimer Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
45 – 85
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
15 (estimated)
Sponsor
Ali Rezai · Other
Who this trial is looking for

This trial is looking for adults aged 45 to 85 with mild cognitive impairment due to Alzheimer's disease. Participants will receive a treatment using focused ultrasound to see if it is safe and tolerable.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 45 and 85 years old.
  • I can give informed consent.
  • I have mild cognitive impairment due to Alzheimer's disease.
  • I have been on stable doses of my current medications for at least 45 days.
  • I can communicate my sensations during the procedure.

You may not be able to join if

  • I cannot undergo MR-imaging due to certain implanted devices.
  • I have scars or disorders on my scalp that cover a large area.
  • I have a history of seizure disorder.
  • I have significant chronic lung problems.
  • I do not speak English.
  • I am pregnant or planning to become pregnant.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Males and non-pregnant females, aged 45-85 years * Able and willing to give informed consent * Must meet the clinical criteria for MCI due to Alzheimer's disease * If receiving concurrent treatment with an AChEI and/or memantine, has been on a stable dose for at least 45 days …
Contacts

Marc Haut, PhD

3042936276

mhaut@hsc.wvu.edu

CONTACT